Sorry, you need to enable JavaScript to visit this website.
Skip to main content


A closer look on how Dr. Reddy's met the stringent regulatory requirement of genotoxic impurities in Ranolazine

Genotoxic impurities (GTIs) have recently challenged the pharmaceutical industry by virtue of their presence at a level of parts per million (ppm) in drug products, especially in high dosage molecules like Ranolazine, which has a prescribed maximum daily dosage (MDD) of 2000 mg.

In this whitepaper, we talk about steps taken by Dr. Reddy's during the product development phase to address this challenge by designing the process in such a way that all these PGIs / GTI’s are within the control in the manufacturing approach followed by Dr. Reddy’s for Ranolazine.

Read our latest whitepaper on this topic by filling the contact form below.

You can also explore our Ranolazine API offering by clicking on the link below:

https://api.drreddys.com/product/ranolazine

Please fill the Contact form below in order to view the white paper

Email us: api@drreddys.com |   +91 40 49002253